Preventive effect of Danshen Dropping Pills on contrast nephropathy and prognosis after percutaneous coronary intervention

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053704

Enrollment

Unknown

Registered

2021-11-27

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast induced nephropathy

Interventions

Experimental group:Danshen Dropping Pills

Control group:Water therapy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Those with clear indications for PCI; 2. No oral Danshen dripping pills within 1 week before PCI; 3. Meet the diagnostic criteria of coronary heart disease guidelines.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to contrast agents; 2. Those undergoing emergency PCI; 3. Those who have taken Danshen dripping pills within 1 week before PCI; 4. Those who have repeatedly used contrast agents within 2 weeks before PCI; 5. Patients with acute heart failure or patients with cardiogenic shock; 6. Hemoglobin less than 8g/L and systolic blood pressure less than 90mmHg; 7. Patients with gastrointestinal bleeding or acute stroke; 8. Patients with severe thyroid dysfunction who cannot use contrast agents; 9. Refuse to participate in this researcher.

Design outcomes

Primary

Measure	Time frame
renal function;	—

Countries

China

Contacts

Public ContactZhang Peng

Tianjin Chest Hospital

peng306588_0@163.com+86 13752686332

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026